Shares of Cassava Sciences Inc. dropped over 10% in after-hours trading following a settlement with U.S. securities regulators over misleading claims about an Alzheimer’s clinical trial. The pharma company and two former executives were charged for the deceptive statements, leading to the stock decline. This development highlights the impact of regulatory actions on stock performance in the pharmaceutical sector.
Full Article
Loading PerspectiveSplit analysis...
